COVID-19: Changes to funding criteria for long-acting muscarinic agonists
We've temporarily removed the requirement for COPD diagnosis using spirometry for long-acting muscarinic agonists
Spirometry requirement changed for glycopyrronium, tiotropium, and umeclidinium
From 1 December 2021, we temporarily removed the requirement for patients to have a diagnosis of COPD using spirometry, if spirometry is not possible due to COVID-19 restrictions.
Schedule listings
Tiotropium bromide(external link)
We intend to return to previous endorsement once health services have stabilised to a point where it's practical to reinstate this requirement.
Who to contact
If you have questions about this funding change, email enquiry@pharmac.govt.nz